Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 9, 2009, Pages 1409-1416

  Kengne Wafo, Severin ^a   Massella, Laura ^a   Diomedi Camassei, Francesca ^a   Gianviti, Alessandra ^a   Vivarelli, Marina ^a   Greco, Marcella ^a   Stringini, Gilda Rita ^a   Emma, Francesco ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAMIPRIL; STEROID;

ADOLESCENT; ARTICLE; CHILD; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; HYPERURICEMIA; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION;

ADOLESCENT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOPSY; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; HYPERURICEMIA; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY DISEASES; LOGISTIC MODELS; MALE; NEPHROTIC SYNDROME; ODDS RATIO; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 73249130184     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01520209     Document Type: Article

References (37)

1. Niaudet P, Habib R, Tete MJ, Hinglais N, Broyer M: Cyclosporin in the treatment of idiopathic nephrotic syndrome in children. Pediatr Nephrol 1: 566-573, 1987
2. Hodson EM, Willis NS, Craig JC: Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev (23): CD002290, 2008
3. Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J: Steroid-resistant idiopathic childhood nephrosis: Overdiagnosed and undertreated. Nephrol Dial Transplant 22: 2183-2193, 2007
4. Niaudet P, Habib R: Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol 5: 1049-1056, 1994
5. Mathieson PW: Proteinuria and immunity: An overstated relationship? N Engl J Med 359: 2492-2494, 2008
6. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P: The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14: 931-938, 2008
7. Tanner JM, Whitehouse RH: Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Intern Med 51: 170-179, 1976
8. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: A working group report from the National High Blood Pressure Education Program: National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Pediatrics 98: 649-658, 1996
9. Schwartz GJ, Gauthier B: A simple estimate of glomerular filtration rate in adolescent boys. Pediatrics 106: 522-526, 1985
10. Mihatsch MJ, Antonovych T, Bohman SO, Habib R, Helmchen U, Noel LH, Olsen S, Sibley RK, Kemény E, Feutren G: Cyclosporine A nephropathy standardization of the evaluation of kidney biopsies. Clin Nephrol 41: 23-32, 1994
11. Jennette JC, Olson JL, Schwartz MM, Silva FG: Pathology of the Kidney, 6th Ed., Philadelphia, Lippincott Williams & Wilkins, 2007, pp 1427-1439
12. Fujinaga S, Kaneko K, Muto T, Ohtomo Y, Murakami H, Yamashiro Y: Independent risk factors for chronic cyclosporine induced nephropathy in children with nephritic syndrome. Arch Intern Med 91: 666-670, 2006
13. Seikaly MG, Prashner H, Nolde-Hurlbert B, Browne R: Long-term clinical and pathological effects of cyclosporine in children with nephrosis. Pediatr Nephrol 14: 214-217, 2000
14. Kranz B, Vester U, Büscher R, Wingen AM, Hoyer PF: Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: Long-term treatment up to 10 years. Pediatr Nephrol 23: 581-586, 2008
15. Ishikura K, Ikeda M, Hattori S, Yoshikawa N, Sasaki S, Iijima K, Nakanishi K, Yata N, Hond M: Effective and safe treatment with cyclosporine in nephrotic children: A prospective, randomized multicenter trial. Kidney Int 73: 1167-1173, 2008
16. Gregory MJ, Smoyer WE, Sedman A, Kershaw DB, Valentini RP, Johnson K, Bunchman TE: Long-term cyclosporine therapy for pediatric nephrotic syndrome: A clinical and histologic analysis. J Am Soc Nephrol 7: 543-549, 1996
17. Nakamura T, Nozu K, Iijima K, Yoshikawa N, Moriya Y, Yamamori M, Kako A, Matsuo M, Sakurai A, Okamura N, Ishikawa T, Okumura K, Sakaeda T: Association of cumulative cyclosporine dose with its irreversible nephrotoxicity in Japanese patients with pediatric-onset autoimmune diseases. Biol Pharm Bull 30: 2371-2375, 2007
18. Iijima K, Hamahira K, Tanaka R, Kobayashi A, Nozu K, Nakamura H, Yoshikawa N: Risk factors for cyclosporine induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 61: 1801-1805, 2002
19. Rinaldi S, Sesto A, Barsotti P, Faraggiana T, Sera F, Rizzoni G: Cyclosporine therapy monitored with abbreviated area under curve in nephrotic syndrome. Pediatr Nephrol 20: 25-29, 2005
20. Nakahata T, Tanaka H, Tsugawa K, Kudo M, Suzuki K, Ito E, Waga S: C1-C2 point monitoring of low-dose cyclosporin a given as a single daily dose in children with steroid-dependent relapsing nephrotic syndrome. Clin Nephrol 66: 219-220, 2006
21. Inoue Y, Iijima K, Nakamura H, Yoshikawa N: Two-year cyclosporine treatment in children with steroid-dependent nephritic syndrome. Pediatr Nephrol 13: 33-38, 1999
22. Ganesan V, Milford DV, Taylor CM, Hulton SA, Parvaresh S, Ramani P: Cyclosporine-related nephrotoxicity in children with nephrotic syndrome. Pediatr Nephrol 17: 225-226, 2002
23. El-Husseini A, El-Basuony F, Mahmoud I, Sheashaa H, Sabry A, Hassan R, Taha N, Hassan N, Sayed-Ahmad N, Sobh M: Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: A single-centre experience. Nephrol Dial Transplant 20: 2433-2438, 2005
24. Hino S, Takemura T, Okada M, Murakami K, Yagi K, Fukushima K, Yoshioka K: Follow up study of children with nephritic syndrome treated with a long-term moderate dose of cyclosporine. Am J Kidney Dis 31: 932-939, 1998
25. Webb KL, Sargent P, Burke JR: Cyclosporin therapy in steroid-dependent nephrotic syndrome. J Paediatr Child Health 29: 188-191, 1993
26. Wyszyńska T, Ksiazek J, Wieteska-Klimczak A, Gorzkowska-Paczwa M, Dorywalski T, Tysarowska A: Evaluation of the efficacy of cyclosporine A treatment in idiopathic nephrotic syndrome in children. Pol Merkur Lekarski 11: 140-143, 2001
27. Niaudet P, Broyer M, Habib R: Treatment of idiopathic nephrotic syndrome with cyclosporine A in children. Clin Nephrol 35[Suppl 1]: S31-S36, 1991
28. Hoyer PF, Lee IK, Oemar BS, Krohn HP, Offner G, Brodhel J: Renal handling of uric acid under cyclosporine A treatment. Pediatr Nephrol 2: 18-21, 1988
29. Tumgor G, Arikan C, Kilic M, Aydogdu S: Frequency of hyperuricemia and effect of calcineurin inhibitors on serum uric acid levels in liver transplanted children. Pediatr Transplant 10: 665-668, 2006
30. Menè P, Punzo G: Uric acid: Bystander or culprit in hypertension and progressive renal disease? J Hypertens 26: 2085-2092, 2008
31. Mazzali M, Kim YG, Suga S, Gordon KL, Kang DH, Jefferson JA, Hughes J, Kivlighn SD, Lan HY, Johnson RJ: Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 71: 900-905, 2001
32. Abuelo JG: Normotensive ischemic acute renal failure. N Engl J Med 357: 797-805, 2007
33. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, doubleblind, controlled trial. Lancet 372: 547-553, 2008
34. Kon V, Hunley TE, Fogo A: Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis: Studies in chronic cyclosporine nephrotoxicity in rats. Transplantation 60: 89-95, 1995
35. Ramírez C, Olmo A, O'Valle F, Masseroli M, Aguilar M, Gómez-Morales M, Revelles F, García-Chicano MJ, Arrebola F, Reguero ME, del Moral RG: Role of intrarenal endothelin 1, endothelin 3, and angiotensin II expression in chronic cyclosporin A nephrotoxicity in rats. Exp Nephrol 8: 161-172, 2000
36. Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WC, Van Der Heijden AJ: Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 23: 2013-2020, 2008
37. Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F: Rituximab treatment for severe steroid- or cyclosporine- dependent nephritic syndrome: A multicentric series of 22 cases. Pediatr Nephrol 23: 1269-1279, 2008